Effect and safety of the new obesity drugs. What value do Orlistat and sibutramine have in the treatment of obesity?;Wie sicher sind die neuen adipositasmedikamente? Indikationen und kontraindikationen von Orlistat und sibutramin

MMW-Fortschritte der Medizin

Volumn 141, Issue 49-50, 1999, Pages 32-36

  Richter, W O ^a  

^a Inst Fettstoffwechsel Hamorheologie   (Germany)

Author keywords

Interactions; Obesity; Orlistat; Sibutramine; Side effects; Weight reduction

Indexed keywords

ANTIOBESITY AGENT; FECES LIPID; NORADRENALIN; SEROTONIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FATIGUE; FECES COMPOSITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIPID ABSORPTION; OBESITY; SATIETY; SEROTONIN UPTAKE; SHORT SURVEY; TREATMENT PLANNING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CLINICAL TRIALS; CYCLOBUTANES; DRUG INTERACTIONS; HUMANS; LACTONES; OBESITY; TREATMENT OUTCOME;

EID: 0033539965     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Apfelbaum, M., Vague, P., Ziegler, O., et al.: Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Amer. J. Med. 106 (1999), 179-184.
2. Davidson, M. H., Hauptman, J., DiGirolamo, M., et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. J. Amer. med. Ass. 281 (1999), 235-242.
3. Hanotin, C., Thomas, F., Jones, S. P., et al.: Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int. J. Obes. Relat. Metab. Disord. 22 (1998), 32-38.
4. Hansen, D. L., Toubro, S., Stock, M. J., et al.: Thermogenic effects of sibutramine in humans. Amer. J. clin. Nutr. 68 (1998), 1180-1186.
5. Hauptmann, J. B., Jeunet, F. S., Hartmann, D.: Initial studies in humans with the novel gastrointestinal lipase inhibitor ro-18-0647 (tetrahydrolipstatin). Amer. J. clin. Nutr. 55 (Suppl.) (1992), 309-313.
6. Hill, J. O., Hauptman, J., Anderson, J. W., et al.: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Amer. J. clin. Nutr. 69 (1999), 1108-1116.
7. Hollander, P. A., Elbein, S. C., Hirsch, I. B., et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21 (1998), 1288-1294.
8. McNeely, W., Benfield, P.: Orlistat. Drugs 56 (1998), 241-249.
9. McNeely, W., Goa, K. L.: Sibutramine. Drugs 56 (1998), 1093-1124.
10. Noack, R.: Two-year study of orlistat in the treatment of obesity. 79th Annual Meeting of the American Endocrine Society 1997.
11. Rissanen, A.: Long-term weight management in obesity with orlistat, a new gastrointestinal lipase inhibitor. Diabetes 46 (Suppl. 1) (1997), 87A.
12. Rolls, B. J., Shide, D. J., Thorwart, M. L., et al.: Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. 6 (1998), 1-11.
13. Van Gaal, L. F., J. I. Broom, J. I., Enzi, G., et al.: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Europ. J. Pharmacol. 54 (1998), 125-132.